168 related articles for article (PubMed ID: 37629650)
1. Double Trouble: Association of Malignant Melanoma with Sporadic and Genetic Forms of Parkinson's Disease and Asymptomatic Carriers of Related Genes: A Brief Report.
Koros C; Simitsi AM; Bougea A; Papagiannakis N; Antonelou R; Pachi I; Angelopoulou E; Prentakis A; Zachou A; Chrysovitsanou C; Beratis I; Fragkiadaki S; Kontaxopoulou D; Eftymiopoulou E; Stanitsa E; Potagas C; Papageorgiou SG; Karavasilis E; Velonakis G; Prassopoulos V; Geronicola-Trapali X; Stefanis L
Medicina (Kaunas); 2023 Jul; 59(8):. PubMed ID: 37629650
[No Abstract] [Full Text] [Related]
2. Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study.
Simuni T; Uribe L; Cho HR; Caspell-Garcia C; Coffey CS; Siderowf A; Trojanowski JQ; Shaw LM; Seibyl J; Singleton A; Toga AW; Galasko D; Foroud T; Tosun D; Poston K; Weintraub D; Mollenhauer B; Tanner CM; Kieburtz K; Chahine LM; Reimer A; Hutten SJ; Bressman S; Marek K;
Lancet Neurol; 2020 Jan; 19(1):71-80. PubMed ID: 31678032
[TBL] [Abstract][Full Text] [Related]
3. Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional Study.
Simuni T; Brumm MC; Uribe L; Caspell-Garcia C; Coffey CS; Siderowf A; Alcalay RN; Trojanowski JQ; Shaw LM; Seibyl J; Singleton A; Toga AW; Galasko D; Foroud T; Nudelman K; Tosun-Turgut D; Poston K; Weintraub D; Mollenhauer B; Tanner CM; Kieburtz K; Chahine LM; Reimer A; Hutten S; Bressman S; Marek K;
Mov Disord; 2020 May; 35(5):833-844. PubMed ID: 32073681
[TBL] [Abstract][Full Text] [Related]
4. The Effect of p.G2019S Mutation in the
Usenko TS; Timofeeva A; Beletskaia M; Basharova K; Baydakova G; Bezrukova A; Grunina M; Emelyanov A; Miliukhina I; Zakharova E; Pchelina S
J Integr Neurosci; 2024 Jan; 23(1):16. PubMed ID: 38287861
[TBL] [Abstract][Full Text] [Related]
5. Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations.
Alcalay RN; Levy OA; Waters CC; Fahn S; Ford B; Kuo SH; Mazzoni P; Pauciulo MW; Nichols WC; Gan-Or Z; Rouleau GA; Chung WK; Wolf P; Oliva P; Keutzer J; Marder K; Zhang X
Brain; 2015 Sep; 138(Pt 9):2648-58. PubMed ID: 26117366
[TBL] [Abstract][Full Text] [Related]
6. [Plasma Exosomes in Inherited Forms of Parkinson's Disease].
Kulabukhova DG; Garaeva LA; Emelyanov AK; Senkevich KA; Gracheva EV; Miliukhina IV; Varfolomeeva EY; Timofeeva AA; Schwartsman AL; Shtam TA; Pchelina SN
Mol Biol (Mosk); 2021; 55(2):338-345. PubMed ID: 33871446
[TBL] [Abstract][Full Text] [Related]
7. Resequencing analysis of five Mendelian genes and the top genes from genome-wide association studies in Parkinson's Disease.
Benitez BA; Davis AA; Jin SC; Ibanez L; Ortega-Cubero S; Pastor P; Choi J; Cooper B; Perlmutter JS; Cruchaga C
Mol Neurodegener; 2016 Apr; 11():29. PubMed ID: 27094865
[TBL] [Abstract][Full Text] [Related]
8. Autosomal dominant Parkinson's disease: Incidence of mutations in LRRK2, SNCA, VPS35 and GBA genes in Brazil.
Abreu GM; Valença DC; Campos M; da Silva CP; Pereira JS; Araujo Leite MA; Rosso AL; Nicaretta DH; Vasconcellos LF; da Silva DJ; Della Coletta MV; Dos Santos JM; Gonçalves AP; Santos-Rebouças CB; Pimentel MM
Neurosci Lett; 2016 Dec; 635():67-70. PubMed ID: 27777137
[TBL] [Abstract][Full Text] [Related]
9. Genetic heterogeneity on sleep disorders in Parkinson's disease: a systematic review and meta-analysis.
Huang J; Cheng Y; Li C; Shang H
Transl Neurodegener; 2022 Apr; 11(1):21. PubMed ID: 35395825
[TBL] [Abstract][Full Text] [Related]
10. Evaluating the Role of SNCA, LRRK2, and GBA in Chinese Patients With Early-Onset Parkinson's Disease.
Chen Y; Gu X; Ou R; Zhang L; Hou Y; Liu K; Cao B; Wei Q; Li C; Song W; Zhao B; Wu Y; Cheng J; Shang H
Mov Disord; 2020 Nov; 35(11):2046-2055. PubMed ID: 32677286
[TBL] [Abstract][Full Text] [Related]
11. Age at Onset of Parkinson's Disease Among Ashkenazi Jewish Patients: Contribution of Environmental Factors, LRRK2 p.G2019S and GBA p.N370S Mutations.
Yahalom G; Rigbi A; Israeli-Korn S; Krohn L; Rudakou U; Ruskey JA; Benshimol L; Tsafnat T; Gan-Or Z; Hassin-Baer S; Greenbaum L
J Parkinsons Dis; 2020; 10(3):1123-1132. PubMed ID: 32310186
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of pre-diagnostic symptoms did not differ between LRRK2-related, GBA-related and idiopathic patients with Parkinson's disease.
Liu SY; Zheng Z; Gu ZQ; Wang CD; Tang BS; Xu YM; Ma JH; Zhou YT; Feng T; Chen SD; Chan P;
Parkinsonism Relat Disord; 2018 Dec; 57():72-76. PubMed ID: 30119933
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive LRRK2 and GBA screening in Portuguese patients with Parkinson's disease: identification of a new family with the LRRK2 p.Arg1441His mutation and novel missense variants.
Zhang L; Quadri M; Guedes LC; Coelho M; Valadas A; Mestre T; Lobo PP; Rosa MM; Simons E; Oostra BA; Ferreira JJ; Bonifati V
Parkinsonism Relat Disord; 2013 Oct; 19(10):897-900. PubMed ID: 23726462
[TBL] [Abstract][Full Text] [Related]
14. Carriers of both GBA and LRRK2 mutations, compared to carriers of either, in Parkinson's disease: Risk estimates and genotype-phenotype correlations.
Yahalom G; Greenbaum L; Israeli-Korn S; Fay-Karmon T; Livneh V; Ruskey JA; Roncière L; Alam A; Gan-Or Z; Hassin-Baer S
Parkinsonism Relat Disord; 2019 May; 62():179-184. PubMed ID: 30573413
[TBL] [Abstract][Full Text] [Related]
15. Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional study.
Siderowf A; Concha-Marambio L; Lafontant DE; Farris CM; Ma Y; Urenia PA; Nguyen H; Alcalay RN; Chahine LM; Foroud T; Galasko D; Kieburtz K; Merchant K; Mollenhauer B; Poston KL; Seibyl J; Simuni T; Tanner CM; Weintraub D; Videnovic A; Choi SH; Kurth R; Caspell-Garcia C; Coffey CS; Frasier M; Oliveira LMA; Hutten SJ; Sherer T; Marek K; Soto C;
Lancet Neurol; 2023 May; 22(5):407-417. PubMed ID: 37059509
[TBL] [Abstract][Full Text] [Related]
16. Revisiting the non-Gaucher-GBA-E326K carrier state: Is it sufficient to increase Parkinson's disease risk?
Goldstein O; Gana-Weisz M; Cohen-Avinoam D; Shiner T; Thaler A; Cedarbaum JM; John S; Lalioti M; Gurevich T; Bar-Shira A; Mirelman A; Giladi N; Orr-Urtreger A
Mol Genet Metab; 2019 Dec; 128(4):470-475. PubMed ID: 31662221
[TBL] [Abstract][Full Text] [Related]
17. Glucocerebrosidase Activity is not Associated with Parkinson's Disease Risk or Severity.
Omer N; Giladi N; Gurevich T; Bar-Shira A; Gana-Weisz M; Glinka T; Goldstein O; Kestenbaum M; Cedarbaum JM; Mabrouk OS; Fraser KB; Shirvan JC; Orr-Urtreger A; Mirelman A; Thaler A
Mov Disord; 2022 Jan; 37(1):190-195. PubMed ID: 34550621
[TBL] [Abstract][Full Text] [Related]
18. CSF total and oligomeric α-Synuclein along with TNF-α as risk biomarkers for Parkinson's disease: a study in LRRK2 mutation carriers.
Majbour NK; Aasly JO; Hustad E; Thomas MA; Vaikath NN; Elkum N; van de Berg WDJ; Tokuda T; Mollenhauer B; Berendse HW; El-Agnaf OMA
Transl Neurodegener; 2020 May; 9(1):15. PubMed ID: 32375873
[TBL] [Abstract][Full Text] [Related]
19. Apathy: An underestimated feature in GBA and LRRK2 non-manifesting mutation carriers.
Pachi I; Koros C; Simitsi AM; Papadimitriou D; Bougea A; Prentakis A; Papagiannakis N; Bozi M; Antonelou R; Angelopoulou E; Beratis I; Stamelou M; Trapali XG; Papageorgiou SG; Stefanis L
Parkinsonism Relat Disord; 2021 Oct; 91():1-8. PubMed ID: 34425330
[TBL] [Abstract][Full Text] [Related]
20. Analysis of the genetic variability in Parkinson's disease from Southern Spain.
Bandrés-Ciga S; Mencacci NE; Durán R; Barrero FJ; Escamilla-Sevilla F; Morgan S; Hehir J; Vives F; Hardy J; Pittman AM
Neurobiol Aging; 2016 Jan; 37():210.e1-210.e5. PubMed ID: 26518746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]